Podcasts about MCR

This week, Brian sits down with Chicago radio personality, comedian, and Riot Fest veteran Kevin Kellam! They dive into the history of Riot Fest, speculate wildly about potential 2025 headliners (and some definite long shots), and rank bands based on likelihood and pure hope. Plus, get all the details on Kevin's upcoming comedy special taping in Chicago this August!Topics Discussed:Kevin Kellam's history with Riot Fest and Chicago radio (Q101, etc.)Speculating and ranking potential Riot Fest 2025 bands (Deftones, TBS, Gwar, MCR, System, Jimmy Eat World, Weird Al, and many more!)The rise of full album plays at festivalsDetails on Kevin's comedy special "Kevin and Hell" taping August 9th at Lincoln HallComparing Riot Fest and Lollapalooza bookings and vibesThe impact of radius clauses and other festival conflicts (Louder Than Life, When We Were Young)Dream festival bookings and reunions (Iron Maiden, The Donnas)

An episode that explores the impact of My Chemical Romance through an autistic and neurodivergent perspective. Matt, Angela, and our sound engineer Simon Scott break down how the band's emotional intensity, justice themes, and outsider energy have made them a lasting icon within the autistic community.Here's what's in store for today's episode: * Today, we're taking a deep dive into My Chemical Romance and exploring how they reflect and embody elements of the autistic experience.* Our podcast producer, sound engineer, and behind-the-scenes magic man, Simon Scott, steps in front of the mic today to talk about his special interest.* We kick things off with the ultimate lore deep dive—tracing the butterfly effect from 9/11 all the way to Ellen DeGeneres getting canceled (yes, it is connected to My Chemical Romance, and yes, it makes sense… eventually).* After witnessing the Twin Towers fall from the Hudson River on 9/11, Gerard Way felt a deep urge to create something bigger than himself—something that could connect people through shared emotion and purpose. Out of that moment, My Chemical Romance was born.* We then dive into how bottom-up processing and autistic hyper-empathy may have influenced Gerard's decision—how taking in overwhelming sensory and emotional details of the moment could have sparked a need to respond in a deeply personal, creative, and connective way.* The band went on to write, produce, perform, and publish their entire first album within a week—a hyperfixation-fueled feat that no neurotypical could realistically pull off with the same intensity, focus, and urgency.* Their albums are deeply narrative, with each one following characters that symbolically represent the band members themselves. The first two albums build a layered universe that culminates in their third release—Welcome to the Black Parade—widely regarded as their magnum opus and a defining moment in emo and alternative music history.* We unpack the imagery in the “I'm Not Okay (I Promise)” music video and how it resonates with many autistic traits—highlighting themes of social rejection, masking, sensory overwhelm, and the desperate need to be understood in a world that constantly misunderstands you.* Next, we explore themes of justice sensitivity woven throughout MCR's lyrics—a trait commonly linked to the autistic experience—and how the so-called “autistic accent” subtly shapes the cadence, rhythm, and emotional delivery of their songs, adding layers of urgency, vulnerability, and authenticity.* Our hosts and Simon dive into the rich subculture that's emerged from the band's work—a world built by and for the outcasts, the overly emotional, the neurodivergent, and those who never quite fit in. MCR didn't just create music—they created a movement, a safe haven, and a language for people who feel everything too much.* Finally, we dive into expectation sensitivity, unpack the reasons behind the band's 8-year hiatus, and reflect on their powerful return—why their message hits harder than ever in today's world and why we still need MCR now more than ever.“I'd rather be a creature of the night than just some old dude.” - Gerard Way“I disappoint a lot of people. They expect me to be one way. If I spend a minute with them, they end up saying, ‘Oh, you're actually just a really nice person. They hate me when they catch me out of my makeup.” - Gerard Way“Neurotypical people tend to do things for power, prestige, and profit. He's not doing it because he wants to maintain the My Chemical Romance empire. He's not doing it because he wants to be famous. He's not doing it because he wants all the money. He has a story to tell. He has a reason for doing the thing.” - MattDid you enjoy this episode? We took a deep dive into the world of My Chemical Romance and how their music, message, and aesthetic embody key aspects of the autistic experience. From the butterfly effect of 9/11 to the cancellation of Ellen (yes, really), we trace the band's origins, explore autistic hyper-empathy and justice sensitivity in their lyrics, and analyze how the “autistic accent” shows up in their sound. Plus, we break down the iconic “I'm Not Okay” music video and the subculture that's made MCR a safe haven for neurodivergent weirdos everywhere. Join the convo with #AutisticCultureCatch!Show Notes:My Chemical Romance on Wikipedia - https://en.wikipedia.org/wiki/My_Chemical_RomanceBlack Parade in Musical Order - Neurodivergent Experience -Na Na Na Music Video: Welcome to the Black Parade Music Video: Related Episodes:Chess is AutisticFreddie Mercury is AutisticFollow us on InstagramFind us on Apple Podcasts and SpotifyLearn more about Matt at Matt Lowry, LPPJoin Matt's Autistic Connections Facebook GroupLearn more about Angela at AngelaKingdon.com Angela's social media: Twitter and TikTokOur Autism-affirming merch shop This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.autisticculturepodcast.com/subscribe

Helané Wahbeh, ND, MCR, is the Director of Research at the Institute of Noetic Sciences and an adjunct assistant professor at Oregon Health & Science University. Dr. Wahbeh is the author of some 90+ peer-reviewed publications and the book The Science of Channeling: Why You Should Trust Your Intuition. Her VET-MIND study was funded by the National Institutes of Health and examined the mechanisms of meditation for combat veterans with PTSD. Her current research interests include healing stress and trauma and extended human capacities. She is a Board Member and Past President of the Parapsychological Association and has been meditating for two decades.    Here she and Dawson discuss: Noetic Signature: experience of our inner wisdom How to differentiate from your ego and your higher self? Exercise: To what question would you like intuitive information? Noetic knowing shows up in one of 12 different ways Meditation: An introduction to the inner world The ability all humans have to access energy and information Types of channelings  Why studies correlate childhood trauma with psychic experiences and mediumship How two studies in UK found that psychic abilities run in families Study comparing the full genome of a psychic to controls Study discovery: a unique noncoding gene on chromosome 7 in the psychic group   To learn more about the Institute of Noetic Sciences: https://noetic.org/   Find Dawson's work at: http://dawsongift.com/   And to order Dawson's newest book, Spiritual Intelligence:  https://www.amazon.com/Spiritual-Intelligence-Activating-Circuits-Awakened/dp/160415294X/   #mindtomatter #blissbrain #spiritualintelligence #eft #meditation #highenergyhealth #channeling #intuition #noetic #ions 

A fever dream of a concert experience. Join us as we recap our time at the MCR album release for Danger Days: The True Lives of The Fabulous Killjoys. There was everything from a Zone 5 carnival to Show Pony dancing on stage...much to Jenn's horror. What a night!Find the music and artists referenced this week here: https://open.spotify.com/playlist/1bmhC0eEetxC2w7IfccYqx?si=16fa230e091e4a06Please send concert/event stories and questions to girlsattherockshowpod@gmail.comPlease follow us on IG, Facebook, and TikTok @girlsattherockshowpod*Note: We plan to read concert/event stories and questions on the podcast so if you would like to remain anonymous, please let us know. Hosted on Acast. See acast.com/privacy for more information.

Twenty five years ago, the idea that our mental state and emotions influence our physical health was taboo. Today, it's common knowledge, and it's being studied extensively all over the world. In this episode, Dr. Helané Wahbeh, a clinically trained naturopathic physician and researcher, and the Director of Research at the Institute of Noetic Sciences, shares how our consciousness is a powerful tool that has an impact on the physical body.We talk about “little c” and “big C” consciousness, our understanding of how the soul and body are connected, mind-body awakening, surrendering your attachment to the outcome of having a baby, and more. When you apply her research to the fertility journey and learn to surrender, amazing things can happen for you. Key Topics/Takeaways:The difference between “little c” and “big C” consciousness. [5:04]Creating positive change through positive intentions. [8:14]The paradox of surrendering the outcome to manifest your desires. [13:11]The theories behind channeling, awakening, and mediumship. [14:09]Honoring your body through acknowledging its inherent consciousness. [28:37]How to tap into your inner wisdom. [30:30]Knowing your underlying motivations for your desires. [36:05]How to connect with Dr. Helané WahbehThe Science of Channeling Book: https://buff.ly/38DmeS1Profile: https://noetic.org/profile/helane-wahbeh/Helané Wahbeh's Bio:Helané Wahbeh, ND, MCR, is the Director of Research at the Institute of Noetic Sciences and an adjunct assistant professor in the Department of Neurology at Oregon Health & Science University. She completed her undergraduate degree at University of California Berkeley in Anthropology and Pre-Medicine. She obtained her clinical doctorate at the National University of Natural Medicine. She obtained her Master of Clinical Research from Oregon Health & Science University where she has been on faculty in the department of neurology since 2006. She also completed two post-doctoral research fellowships.Her VET-MIND study funded by the National Institutes of Health examined the mechanisms of meditation for combat veterans with PTSD. Her current research interests include healing stress and trauma, examining mechanisms of mind-body medicine, and rigorously studying extended human capacitiesDr. Wahbeh is the author of some 90+ peer-reviewed publications and the book The Science of Channeling: Why You Should Trust Your Intuition and the Force That Connects Us All. How to connect to Lorne Brown online and in person (Vancouver, BC)Acubalance.ca book virtual or in person conscious work sessions with Dr. Lorne Brown Lornebrown.comConscious hacks and tools to optimize your fertility by Dr. Lorne Brown:

Thank you for joining us on this special episode of the Misfits Media Podcast. On this special episode, Kirk Burkhead joins us to discuss the 2025 Muddy Creek Rimfire series. The MCR is a rimfire (.22lr) hunter style match series located near Coffey, Missouri. Several of the Misfits have attended previous MCR matches and they are always a good time. We hope you enjoy this episode and consider registering for an upcoming match.Muddy Creek RimfireFacebook:https://www.facebook.com/muddycreekrimfirePractiscore:https://practiscore.com/muddy-creek-rimfire-team-hunter-match-02-22-2025/register Misfits Media PodcastEmail:misfitsmediagroup@gmail.comPatreon:https://patreon.com/MisfitsMediaPodcastYouTube:https://www.youtube.com/@Misfits_Media_PodcastFB:https://www.facebook.com/people/Misfits-Media-Podcast/61559504157666/IG:https://www.instagram.com/misfits_media_podcast/Firearms Radio Network:https://firearmsradio.net/category/podcasts/misfits-media/X:https://x.com/LeftEdgeSendItRumble:https://rumble.com/c/MisfitsMediaPodcastTrigger Hill:https://triggerhill.com/Misfits_Media_Podcast Sponsors:Title Sponsor: A&J Sportinghttps://aandjsporting.com/Use code ‘MM10' for 10% offqualifying purchases Affiliate Sponsor: Travis's GarageWoodworking and Laser EngravingEmail:tgwoodandlaser@gmail.comFacebook:https://www.facebook.com/profile.php?id=61557696364367&sk=aboutInstagram:https://www.instagram.com/tgwoodlaser/ Affiliate Sponsor: Red MistTripodsWebsite:https://www.red-mist-tripods.com/Facebook:https://www.facebook.com/people/RED-MIST-Tripods/61556579574054/Instagram:https://www.instagram.com/red_mist_tripods/ Full Circle Reloading &Firearms:Website:https://fullcirclereloading.com/homeYouTube:https://www.youtube.com/@FullCircleReloading 2nd Amendment Organizations:Gun Owners of America:https://www.gunowners.org/Firearms Policy Coalition:https://www.firearmspolicy.org/Second Amendment Foundation:https://saf.org/

The crew heads out on behalf of the UN, MCR, and Transport Union to find survivors from the non-responsive systems after the Free Navy Conflict. But what could cause a colony of 1,800 Martians to go dark? Abraxas' Precipice is an actual play of The Expanse Roleplaying Game by Green Ronin Publishing. based on the novels by James S.A. Corey. It airs live on Wednesdays at 6pm PST on twitch.tv/onlyplaywizards Get more Abraxas' Precipice: linktr.ee/abraxasprecipic Abraxas' Precipice GameMaster: John Bultena linktr.ee/onlyplaywizards Abraxas' Precipice players are: Donna Prior (they/them) as Myrtle Cooper linktr.ee/Danicia Michael C. Hsiung (he/him) as Waxor DuChang instagram.com/michaelchsiung Scott Mitchell (he/him) as Wyatt Thompson instagram.com/smitchell22 Claire Lewis (she/her) as Ghaz Wheatley bsky.app/profile/beautybot.bsky.social  

This is the second part of John Fox's chat with Manchester radio stalwart Adam Cole. Catch up on part one if you've not heard it yet... ... because this episode he swaps Moss Side for Miami. Hear about how this hot jock ended up reading the news; presenting a breakfast show with his boss; and probably the most uncompassionate and brutal sacking we've ever heard about ("In for a penny, I've got nothing to lose"). It's a rollercoaster.   Adam's current project is the spiky upstart in the MCR radio market, and it's rather good. Have a listen: https://www.thisisthebuzz.com/ Here's some classic Cole cuts: https://aircheckdownloads.com/audio-search?term=adam+cole&sort_bef_combine=relevance_DESC   Help keep the Crunch & Roll episodes coming, and support us on Ko-fi: https://ko-fi.com/crunchandroll  

shaft /ʃɑːft/ verb past tense: shafted; past participle: shafted vulgar slang, informal treat (someone) harshly or unfairly.   There are moments in some people's career where they're riding on the crest of a wave and an exciting new challenge comes along and tempts them away with promises that are too good to say no to. Then… see above. Adam Cole is a stalwart of the Manchester radio scene and has been for a very long time. In fact, he's worked at every major station in the market there, and at one notable example FOUR times. His Galaxy breakfast show was legendary, hugely successful and multi award-winning. And it's probably his success there that set the scene for what was to come. In this episode we find out why he got sacked from hospital radio, which legend he eagerly got CDs out for before his breakfast show, and hear about a wind up call that went a bit too well. This is the first of two episodes with Adam – look out for the second on this feed very soon.   Adam's current project is the spiky upstart in the MCR radio market, and it's rather good. Have a listen: https://www.thisisthebuzz.com/ Here's some classic Cole cuts: https://aircheckdownloads.com/audio-search?term=adam+cole&sort_bef_combine=relevance_DESC   Help keep the Crunch & Roll episodes coming, and support us on Ko-fi: https://ko-fi.com/crunchandroll  

El gobierno cubano comenzó este 15 de enero a liberar a presos políticos como parte del compromiso con Estados Unidos, luego de que Washington sacara a la Habana de la lista de los países que financian al terrorismo. “¿Cómo cree que me voy a sentir? Salir de un infierno, estar con mi familia y con mi hija, tranquilo. Me siento contento”, fueron las primeras palabras de Dariel Cruz al llegar a su barrio en La Habana, la capital de Cuba, tras ser liberado temprano este miércoles. Alegría mesuradaCruz es uno de los 553 presos que el régimen cubano liberará tras una mediación del Vaticano que terminó con un inesperado cambio en la política del mandatario estadounidense Joe Biden hacia la isla. Familiares de los excarcelados indican que recibieron muy temprano una llamada telefónica para anunciarles su salida de la cárcel. “Ellos no van a ser puestos en libertad totalmente. Ellos van a salir con libertad condicional, con licencia extrapenal y con sanciones subsidiarias. Y muchos de ellos ya estaban próximos a cumplir su condena. Por ejemplo, hoy hablé con tres y les quedaban dos o tres meses para extinguir la sanción”, reacciona el opositor Librado Linares García, secretario general del Movimiento Cubano Reflexión (MCR), liberado en 2011 tras ocho años de prisión. “De cualquier manera, yo siento mucha alegría. Yo fui un preso político y también fui puesto en libertad. Y esa sensación de estar en la calle, por supuesto, da alegría”, añade.Amnistiar y pedir perdónLas autoridades cubanas no han dado mayores precisiones sobre el supuesto acuerdo para la liberación de estos presos. Desde la oposición piden dejar de usar a los detenidos como moneda de cambio. Leer tambiénBiden da un giro en su política hacia Cuba y la isla anuncia la liberación de 553 presos políticosSegún Librado Linares García, “Cuba lo que necesita no es un indulto selectivo de 553 presos políticos, hay 1.161. Lo que se necesita es una amnistía. Amnistía significa el perdón. Las causas por las cuales fueron puestos en libertad deben ser retiradas del Código Penal y, en consecuencia, pedirles perdón a esas personas, porque ellos lo único que hicieron fue ejercer los derechos: derecho de manifestación, de protesta pública pacífica, de reunión, de asociación. A veces lo enmascaran con otros delitos, pero en la esencia del problema está eso”. “Hay un descontento muy grande”Una buena parte de los que serán liberados en estos días en Cuba son los presos detenidos tras las históricas protestas del 11 de julio de 2021. Una represión que frenó las manifestaciones, pero no el descontento social.  “Siguen entrando cientos de presos políticos a las cárceles cubanas. Lo que pasa es que como no son tantos de golpe, como fue a raíz de las protestas, quizás no llamen tanto la atención, pero sí el presidio político en Cuba sigue engrosando de nuevos presos”, subraya el secretario general del Movimiento Cubano Reflexión.“Hay un Estado policiaco, hay un conjunto de factores y situaciones que se dan en un régimen totalitario. En alguna medida han contenido las protestas, pero sí hay un descontento muy grande”, concluye.La Habana no reconoce la existencia de presos políticos y acusa a los opositores de ser mercenarios de Estados Unidos. 

El gobierno cubano comenzó este 15 de enero a liberar a presos políticos como parte del compromiso con Estados Unidos, luego de que Washington sacara a la Habana de la lista de los países que financian al terrorismo. “¿Cómo cree que me voy a sentir? Salir de un infierno, estar con mi familia y con mi hija, tranquilo. Me siento contento”, fueron las primeras palabras de Dariel Cruz al llegar a su barrio en La Habana, la capital de Cuba, tras ser liberado temprano este miércoles. Alegría mesuradaCruz es uno de los 553 presos que el régimen cubano liberará tras una mediación del Vaticano que terminó con un inesperado cambio en la política del mandatario estadounidense Joe Biden hacia la isla. Familiares de los excarcelados indican que recibieron muy temprano una llamada telefónica para anunciarles su salida de la cárcel. “Ellos no van a ser puestos en libertad totalmente. Ellos van a salir con libertad condicional, con licencia extrapenal y con sanciones subsidiarias. Y muchos de ellos ya estaban próximos a cumplir su condena. Por ejemplo, hoy hablé con tres y les quedaban dos o tres meses para extinguir la sanción”, reacciona el opositor Librado Linares García, secretario general del Movimiento Cubano Reflexión (MCR), liberado en 2011 tras ocho años de prisión. “De cualquier manera, yo siento mucha alegría. Yo fui un preso político y también fui puesto en libertad. Y esa sensación de estar en la calle, por supuesto, da alegría”, añade.Amnistiar y pedir perdónLas autoridades cubanas no han dado mayores precisiones sobre el supuesto acuerdo para la liberación de estos presos. Desde la oposición piden dejar de usar a los detenidos como moneda de cambio. Leer tambiénBiden da un giro en su política hacia Cuba y la isla anuncia la liberación de 553 presos políticosSegún Librado Linares García, “Cuba lo que necesita no es un indulto selectivo de 553 presos políticos, hay 1.161. Lo que se necesita es una amnistía. Amnistía significa el perdón. Las causas por las cuales fueron puestos en libertad deben ser retiradas del Código Penal y, en consecuencia, pedirles perdón a esas personas, porque ellos lo único que hicieron fue ejercer los derechos: derecho de manifestación, de protesta pública pacífica, de reunión, de asociación. A veces lo enmascaran con otros delitos, pero en la esencia del problema está eso”. “Hay un descontento muy grande”Una buena parte de los que serán liberados en estos días en Cuba son los presos detenidos tras las históricas protestas del 11 de julio de 2021. Una represión que frenó las manifestaciones, pero no el descontento social.  “Siguen entrando cientos de presos políticos a las cárceles cubanas. Lo que pasa es que como no son tantos de golpe, como fue a raíz de las protestas, quizás no llamen tanto la atención, pero sí el presidio político en Cuba sigue engrosando de nuevos presos”, subraya el secretario general del Movimiento Cubano Reflexión.“Hay un Estado policiaco, hay un conjunto de factores y situaciones que se dan en un régimen totalitario. En alguna medida han contenido las protestas, pero sí hay un descontento muy grande”, concluye.La Habana no reconoce la existencia de presos políticos y acusa a los opositores de ser mercenarios de Estados Unidos. 

Ranking every My Chemical Romance album with Aidan Valentine of Superglue! Follow Pop-Punk & Pizza on socials! https://www.instagram.com/poppunkpizzapod/  https://www.facebook.com/poppunkpizzapod  https://www.tiktok.com/@poppunkpizzapod  https://www.threads.net/@poppunkpizzapod  Patreon: https://www.patreon.com/c/poppunkpizzapodcast/membership Don't forget to Subscribe!! https://www.youtube.com/@pop-punkpizzapodcast8793  tags: #music #poppunk #punk #emo #alternative #alt #altmusic #alternativemusic #recordcollection #MCR #rockmusic #podcast

Sálmar 105 Jól hava eingaljóð 110 Í Betlehem, í Dávids stað 116 Himmalsins harpur tóna hátt - 132 Føgur er foldin 95 Gleðilig jól  Kirkjutænarar: Elsa Johanna Høgenni, deknur Anna Sofía Restorff, klokkari Leif Hansen, organistur Uni Næs, dómpróstur Kamarkórið syngur Kringvarp Føroya: Jóhannes Berthelsen, sjónvarpsframleiðari Finnur Hansen, ljóðtøkningur Brandar Heðinsson, MCR og undirtekstir   Samskipað hevur Armgarð Arge

Vascular cognitive impairment is a common and often underrecognized contributor to cognitive impairment in older individuals, with heterogeneous etiologies requiring individualized treatment strategies.  In this episode, Katie Grouse, MD, FAAN speaks with Lisa C. Silbert, MD, MCR, FAAN, an author of the article “Vascular Cognitive Impairment,” in the Continuum December 2024 Dementia issue. Dr. Grouse is a Continuum® Audio interviewer and a clinical assistant professor at the University of California San Francisco in San Francisco, California. Dr. Silbert is is co-director at Oregon Alzheimer's Disease Research Center, a Gibbs Family Endowed professor of neurology, a professor of neurology at Oregon Health & Science University, a staff neurologist, director of Cognitive Care Clinic, and director of the Geriatric Neurology Fellowship Program at Portland Veterans Affairs Health Care System in Portland, Oregon. Additional Resources Read the article: Vascular Cognitive Impairment Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Full transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, which features conversations with Continuum's guest editors and authors who are the leading experts in their fields. Subscribers to the Continuum Journal can read the full article or listen to verbatim recordings of the article and have access to exclusive interviews not featured on the podcast. Please visit the link in the episode notes for more information on the article, subscribing to the journal, and how to get CME. Dr Grouse: This is Dr Katie Grouse. Today I'm interviewing Dr Lisa Silbert about her article on vascular cognitive impairment, which is part of the December 2024 Continuum issue on dementia. Welcome to the podcast and please introduce yourself to our audience.  Dr Silbert: Hi Katie. Thanks for having me here today. Like you mentioned, my name is Lisa Silbert. I am a behavioral neurologist at Oregon Health and Science University and my research focus is in the area of vascular contributions to cognitive impairment and dementia. Dr Grouse: It's such a pleasure to have you and I really enjoyed reading your article. Just incredibly relevant, I think, to most practicing general neurologists, and really to any subspecialty. I'd like to start by asking, what do you think is the main takeaway point of your article for our listeners?  Dr Silbert: Yeah. I think, you know, the field of vascular cognitive impairment has changed and evolved over the last several decades. And I would say the main take-home message is that vascular cognitive impairment or vascular dementia is no longer a diagnosis that is only considered in someone who's had acute decline following a clinical stroke. That we have to expand our awareness of vascular contributions to cognitive impairment and consider other forms of the disease that can cause a more subacute or slowly progressive form of cognitive impairment. And there are many, many forms of vascular cognitive impairment that present in a more slowly progressive manner. The other thing I would say as a major take-home message is that we know that cerebrovascular disease is a very common copathology with other forms of dementia and that it lowers one 's threshold for manifesting cognitive impairment in the context of multiple pathologies. And so, in this way, vascular cognitive impairment should be considered as a contributing and potentially modifiable factor in any dementia.  Dr Grouse: I found that last point just really, really fascinating. And also, you know, the reminder that a combination of pathologies are more common than any one. To your initial point, I'm actually curious, could you kind of outline for us how you approach diagnosing vascular cognitive impairment?  Dr Silbert: Yeah. So with everything in neurology, a lot of it comes down to the initial history taking. And so part of the work up always includes a very detailed history of the presentation of cognitive impairment. Any time there is an acute change in cognition, vascular contribution should be considered, particularly if it's in the context of a clinical stroke or some kind of event that might have lowered cerebral blood flow to the brain. And then having said that, I already mentioned there are many forms of vascular cognitive impairment that can mimic neurodegenerative disease in terms of its course. So being more slowly progressive. And so because of that neuroimaging, and in particular MRI, has become an extremely valuable tool in the workup of anyone who presents with cognitive impairment in order to evaluate contributions from cerebral vascular disease. And so, MRI is a really helpful tool when it comes to teasing out what may be contributing to a patient's clinical syndrome, as well as their other comorbid medical issues, including stroke risk factors and other kind of medical conditions that might contribute to reduce cerebral blood flow. Dr Grouse: I'd love to talk a little bit more about that. You know, as is often the case with neurologic disease associated with vascular pathology, the importance of prevention, you know, focusing on prevention of vascular diseases is so important. What are some things that we can make sure to focus on with our patients and, you know, particularly anything new to be aware of in counseling them? Dr Silbert: Yeah, I'm really glad you asked me that question because like I mentioned, you know, cerebral vascular disease is so common, it lowers one's threshold for cognitive impairment in the face of other age-related brain pathologies. And so, it's really important for all of us to focus on preserving our cognitive health, even starting in midlife. And so, there are a number of areas that I counsel my patients on when it comes to preserving cerebral health and maximizing cerebrovascular health. And so, these stem from the American Heart Association's Life's Essential 8 because we know that preserving cardiovascular health is likely going to also preserve cerebral vascular health. And so, some of the things that I'm very commonly discussing with my patients are controlling stroke risk factors such as blood pressure, blood sugars and cholesterol, maintaining a healthy weight, and then also working towards a lifestyle that includes a healthy diet, no smoking, regular exercise. And then new within the last couple years is also the recommendation that people get adequate sleep, which is something that hasn't been focused on previously. Dr Grouse: I was really interested in reading your article to learn about enlarged perivascular spaces and the role as a mediating factor in the interaction between through a vascular dysfunction and development and progression of neurodegenerative pathology. Can you elaborate on this further? Dr Silbert: So, this is an area that's still largely unknown in the field, and it's an area where there's a lot of emerging work being done. The short answer is, we really don't know with great certainty how it directly connects with accumulating Alzheimer's pathology. But there is some evidence to suggest that the perivascular space is involved in the clearance of toxic solutes from the brain, including Alzheimer's disease pathology. And so there's a lot of work looking at how potentially cerebrovascular risk factors might affect the clearance of those toxic solutes through the perivascular space, including pulse pressure changes that might occur with accumulating cerebrovascular disease and other potential contributors. But one thing I can say with more certainty is that the, you know, location of perivascular spaces is thought to help distinguish those who might have cognitive symptoms due to cerebrovascular disease versus due to cerebral amyloid angiopathy. Or I guess I should say location is helpful in terms of recognizing vascular contributions to cognitive impairment that's due to arteriolosclerosis versus that due to cerebral amyloid angiopathy. In so much that… when we see a lot of perivascular spaces in the basal ganglia in the subcortical structures, that is thought to be more associated with arteriolosclerosis and hypertension type related vascular cognitive impairment. Whereas when we see multiple perivascular spaces within the centrum semiovale, that tends to be more associated with cerebral amyloid angiopathy. Dr Grouse: That's so interesting. And on the topic ofcerebral amyloid angiopathy, you did go into this a good deal. And you know, I think I encourage everybody to revisit the article to remind themselves about, you know, the findings that can increase the suspicion of tribal amyloid angiopathy. However, you also talked about transient focal neurologic episodes, which I think is just a great reminder that, you know, these can occur in this setting and definitely not to miss. Tell us more about what to look for with these types of episodes.  Dr Silbert: Transit focal neurologic episodes can be very difficult to tease apart from a transient ischemic attack. And these transient focal neurologic episodes due to CAA can present in a number of different ways. And I think the important take home message for that is that in people who have neuroimaging evidence of CAA to inform them that they are at increased risk for having these focal neurologic episodes and that if they do present to a hospital or an emergency department with any kind of neurologic event, that those treating them are aware that they have evidence of CAA on their neuroimaging because the treatment of course is quite different. So, it's someone presenting with ATIA who has transient neurologic symptoms might be considered urgently to get a thrombolytic or, you know, TPA, whereas someone who has known cerebral amyloid angiopathy or suspected CAA, they likely already have microbleeds on their neuroimaging and in those cases thrombolytics and TPA would be contraindicated and not helpful in terms of the etiology of their neurologic symptoms. Dr Grouse: That's a really good point to make. And I think also in your article you mentioned the use of aspirin if you're suspecting ATIA versus a, you know, a transient amyloid related focal neurologic episode. You know, one you would treat with aspirin and the other one you wouldn't.  Dr Silbert: That's right.  Dr Grouse: Another sort of interesting topic you delved into was cerebral microinfarct and how this can also contribute to vascular impairment. Could you elaborate a little more on that? Dr Silbert: Yeah. So cerebral microinfarcts are kind of the hidden cause of or a hidden cause of vascular cognitive impairment. And it's extremely challenging because by definition they are not visible on routine clinical neuroimaging. It's something that we are more aware of based on pathological studies and neuroimaging studies that have been done at ultra-high field strength like 7T MRI. And so, we are just learning more about how prevalent they are in certain conditions and how we can only look at these after death when we're looking at brain tissue and then go back and realize that these play a significant role in cognitive decline when someone is alive. It's important to understand that we're probably only appreciating kind of the tip of the iceberg when we're evaluating a patient and looking at their neuroimaging. That what we're actually seeing on MRI are only the things that are actually quite relatively big and obvious. And that a lot of these neuroimaging features of vascular cognitive impairment are actually associated with pathologic features that we're missing such as microinfarcts. But the hope is that by treating all individuals, particularly those who already have signs of vascular cognitive impairment, by modulating their stroke risk factors and focusing on maintaining brain health, that those will, interventions will also reduce the incidence of microinfarcts. Dr Grouse: What do you think is the greatest inequity or disparity you see in treating patients with vascular cognitive impairment? Dr Silbert: I think the greatest disparity is- really starts way before I treat a patient. That relates to really focusing on healthy lifestyle factors early in life and being able to, you know, afford fruits and vegetables, and having the advantages of being able to exercise regularly, and just being aware that all of these things are extremely important before older age. So, these are things that, you know, I think more education and awareness and greater access to healthcare will definitely improve access to. Even preventative healthcare is a disparity and not available across all of the population and geographic locations. So, I think of the- all the dementias, vascular cognitive impairment probably has the greatest association with health and social disparities in terms of primary prevention and access to care.  Dr Grouse: All really important things to consider. I have to say when, you know, reading your article, dare I say I came away with a little bit of hope thinking, you know, even with, you know, how little we still, you know, or how much we still need to do to really learn how to fight Alzheimer's and, you know, prevent it and, and, you know, help with its progression. The idea that in so many cases, even just doing what we can to prevent the vascular or cognitive impairment can really help any type of dementia. That was really a strong message for me. Do you mind elaborating on that a little more?  Dr Silbert: No, not at all. I agree. I really am hopeful about the prevention and treatment of dementias and through the treatment and prevention of cerebrovascular disease. I think that is a true reality, just like, you know, as we were discussing before, the treatment and prevention of cerebrovascular disease really should be a part of the treatment of any type of cognitive impairment and recommendations for prevention of cognitive impairment. This is the, you know, one thing we know is largely modifiable and preventable in most cases. I think the, really the key thing is just education and making sure that people understand that these are things that really need to be, they need to be engaged in in midlife and that it's much harder to reverse these- the damages once you have them in later life. Having said that, I do think that there's greater awareness of maintaining healthy lifestyle and maintaining awareness of stroke risk factors. And I think we're already starting to see a reduction in dementia worldwide in several large population-based studies, and probably that is due to more attention to the modifying stroke risk factors. So, I agree with you, it's very encouraging.  Dr Grouse: Is there anything exciting on the horizon that you can tell us about that we should all be keeping our eyes out for? Dr Silbert: Yeah. So, you know, I'm really interested in this connection between vascular cognitive impairment and Alzheimer's disease. And it's a real area of exciting new research. And so I think we're going to have more answers as to how, whether and how, cerebrovascular disease is directly linked to accumulating neurodegenerative disease or neurodegenerative pathologies. The other area that's, I think, really exciting, that's moving forward, is the in the area of blood-based biomarkers for vascular cognitive impairment. As these emerge, we'll be able to really identify those at greatest risk for vascular cognitive impairment, but also identify novel mechanisms that lead to VCI that can be targeted for therapeutic intervention. Dr Grouse: Well, I'm really excited to see what's coming down the pipeline and what more we'll learn in this area. So, thank you so much for everything you've done to contribute to this field. Dr Silbert: Yeah.  Dr Grouse: I wanted to ask a little bit more about you. What drew you to this work?  Dr Silbert: Well, actually, so my very first published manuscript in medical school was a case report and review on MELAS, which is mitochondrial encephalopathy with lactic acidosis and strokelike syndrome. And so, I was really fortunate to have Dr Jose Biller, who is a renowned expert in stroke and cerebrovascular disorders, as my mentor for that paper. And so, that got me really interested in neuroimaging findings of cerebral vascular disease. And so when I was a fellow at Oregon Health and Science University, I was then really fortunate to  be able to work with Jeffrey Kaye's oldest old population. And in working with that population, I really became interested in their neuroimaging findings of these white matter lesions and just realizing how prevalent they were in that population, you know, it just led me to start investigating their clinical significance and etiology, which kind of led me along this path. Dr Grouse: You know, Lisa, thank you so much. I really learned a lot from your article, and I think our listeners will definitely find that it was very helpful for their practice. Thank you so much for joining us. Dr Silbert: Thank you so much, Katie. It's been really fun.  Dr Grouse: Again, today I've been interviewing Dr Lisa Silbert, whose article on vascular cognitive impairment appears in the most recent issue of Continuum on dementia. Be sure to check out Continuum audio episodes from this and other issues. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, associate editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/AudioCME. Thank you for listening to Continuum Audio.

How many songs can you recognize by hearing the very first note? Just one note, nothing more. Usually when radio stations play that game where they will give you a prize if you can recognize a quick snippet of a song, they give you at least a few notes, even a few seconds. But there is one song out there, and maybe the only one that immediately comes to mind, where if you know that first note, you’d guess it every time. If you’re near a piano or keyboard try playing a G note. What immediately comes to mind? If you thought of My Chemical Romance's 'Welcome to the Black Parade' - you're in for a treat - because the season finale of Encore is all about their 2006 hit - with newly unearthed audio from MCR!

A assinatura do acordo de livre comércio entre os países do Mercosul e da União Europeia causa, oficialmente, reações negativas da França, mas também leva diversos setores econômicos do país a celebrar. Industriais em variadas áreas e fabricantes de produtos agroalimentares, como vinhos e queijos, não veem a hora de o tratado entrar em vigor.  Lúcia Müzell, da RFI em ParisO barulho dos agricultores franceses, que prometem continuar a bloquear a ratificação do acordo, abafa o entusiasmo dos produtores de vinho – ansiosos pela ampliação dos mercados de exportação para países onde o consumo está em plena ascensão, como na América Latina. Jean-Marie Fabre, presidente do Vignerons Indépendants de France, federação sindical que representa 60% da produção francesa e 65% das receitas, ressalta que, enquanto a União Europeia reluta, países produtores como a Austrália, os Estados Unidos e a África do Sul aceleram os acordos comerciais para diminuir os impostos sobre os vinhos exportados.  "Eu peço que a gente assine este acordo, porque o dia em que conseguirmos baixar a zero as tarifas alfandegárias, que hoje são de 27% para os nossos produtos, nós ganharemos com certeza uma grande participação de mercado. Poderemos melhorar o desempenho econômico do nosso setor, mas também da França”, avalia. A Vignerons Indépendants reúne pequenos, médios e grandes produtores, para os quais as exportações representam cerca de 35% das vendas. Noventa por cento deles vendem para outros países da União Europeia e 81% para mercados externos ao bloco.  Fabre cita o exemplo do acordo em vigor com o Japão, que permitiu aos viticultores franceses aumentarem 10% do volume de exportações ao país asiático. A expectativa é ainda mais favorável com os latino-americanos e, em especial, o Brasil.“O Brasil é um país onde o consumo avança a um ritmo de dois dígitos, de 12%, 15%. O Paraguai e o Uruguai estão bem mais atrás. Eu acho que, num primeiro momento, o impulso vai ser relativamente fraco em termos de volume, mas nos próximos 10 a 15 anos, será uma zona do mundo importante de consumo de vinhos e destilados”, espera. "Nós percebemos que é nestes mercados emergentes que a França não deve perder mais tempo e ficar atrasada ou prejudicada por regras de comércio diferentes dos seus concorrentes.”Vinho, carro-chefe do setor agrícola francêsO setor vinícola é o que apresenta, de longe, o melhor desempenho da agricultura francesa. O vinho tem um peso importante no comércio exterior do país: situa-se logo atrás do setor aeronáutico e em pé de igualdade com o luxo, duas atividades que também festejam a assinatura do acordo comercial com o Mercosul, assim como as indústrias química, automotiva, farmacêutica e cosmética. Leia tambémCríticas de CEO do Carrefour à carne brasileira ilustram ‘falta de visão', em meio a crise do varejo na FrançaNo ramo alimentar, os fabricantes de produtos transformados e laticínios se somam à lista, mas a rusga dos pecuaristas contra a carne latino-americana leva os produtores de derivados do leite a serem mais discretos quanto à aprovação do acordo. Quarenta mil toneladas de queijo e 10 mil de leite em pó passarão a entrar no Mercosul com imposto zero, dez anos após a entrada em vigor do tratado.  “O princípio de um acordo é que seja olhado em uma escala global. Não podemos olhar uma corporação em particular, senão nunca vamos assinar nada, e estou bastante persuadido que, no fundo, o governo francês sabe que este tratado seria benéfico para França”, indica o economista especialista em comércio internacional Jean-Marie Cardebat, professor da Universidade de Bordeaux. "Neste momento, a política francesa está bastante lamentável e por razões de cálculos eleitorais mesquinhos, vamos derrubar um acordo que é extremamente importante para a economia francesa”, lamenta.Acordo é equilibrado e favorece os dois lados, diz professorA volta de Donald Trump ao poder nos Estados Unidos, trazendo com ele o aumento das tarifas de importação no país, são uma razão a mais para a França não menosprezar os benefícios do tratado com o Mercosul, avalia o economista.“Este acordo tem uma dupla importância, e muito além do setor dos vinhos. Primeiro, a importância simbólica, em um mundo cada vez mais protecionista, ele é um ato de abertura de mercados que me parece importante e enviaremos uma mensagem para o resto do mundo: a Europa e o Mercosul vão continuar no jogo do comércio mundial”, considera Cardebat. "E segundo, do ponto de vista econômico, todos os modelos, tanto no Brasil, quanto na Europa, indicaram que é um acordo ganha-ganha, sem assimetrias ou desequilíbrios."  O caminho até a ratificação do acordo assinado no dia 6 de dezembro promete ser longo. Na Europa, o texto precisa ser aprovado pelo Parlamento Europeu e o Conselho da União Europeia, os órgãos decisórios da UE. Por enquanto, não há prazo para a sua entrada em vigor.  A redução das tarifas prevista no texto poderá ser imediata ou gradual, de quatro a até 15 anos, conforme o setor. A termo, mais de 90% das exportações europeias para o Mercosul serão beneficiadas, no que será uma das maiores áreas de livre comércio do mundo. O bloco formado por Brasil, Argentina, Paraguai e Uruguai representa um mercado de 270 milhões de consumidores – 80% deles estão no Brasil. Atualmente, o país é 27º destino das exportações francesas.  

We discuss the psycotic MCR fans celebratnig their former drummers death and get deep into our spotify wrapped. Also, this ep has one of the greatest riff session in DTL history. Please listen to it. For the love of god. PLEASE.

On this issue of the Comic Corner, Damon & TJ sit down to talk about the best new books of the week including Absolute Superman, The Ultimates & Christmas 365 by Mikey Way and Jon Rivera. All that and a critical breakdown of Diamond's lack of distributions over the past few weeks.(00:00) The Rundown(01:38) Diamond Delays Again(06:07) Absolute Superman(15:58) The Ultimates(20:42) Christmas 365(24:10) The Incredible Hulk(27:31) Flavor Girls: Return To The Mothership(32:21) Next Week's Pulls

This week we talk about the biggest news stories and social media stories including moancore, the MCR tour announcement and a band member who lied to fans to raise moneyGive us a follow: IG/Twitter: @wewearblackpod Email: wewearblackpod@gmail.com SophieIG/X: @iamsophiek Tiktok: @iamsophiekx YasmineIG: @yasminesumman X/TikTok: @yasminesummanx Special thanks to:Nova Twins for the intro/outro musicWargasm for the screams Hosted on Acast. See acast.com/privacy for more information.

In this episode, Lyell K. Jones Jr, MD, FAAN, speaks with Lisa C. Silbert, MD, MCR, FAAN, who served as a guest editor of the Continuum® December 2024 Dementia issue. They provide a preview of the issue, which publishes on December 2, 2024. Dr. Jones is the editor-in-chief of Continuum: Lifelong Learning in Neurology® and is a professor of neurology at Mayo Clinic in Rochester, Minnesota. Dr. Silbert is co-director at Oregon Alzheimer's Disease Research Center, a Gibbs Family Endowed professor of neurology, a professor of neurology at Oregon Health & Science University, a staff neurologist, director of Cognitive Care Clinic, and director of the Geriatric Neurology Fellowship Program at Portland Veterans Affairs Health Care System in Portland, Oregon. Additional Resources Continuum website: ContinuumJournal.com Subscribe to Continuum: shop.lww.com/Continuum More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @LyellJ Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology, clinical review and CME journal from the American Academy of Neurology.  Thank you for joining us on Continuum Audio, a companion podcast to the journal.  Continuum Audio features conversations with the guest editors and authors of Continuum who are the leading experts in their fields. Subscribers to the Continuum Journal have access to exclusive audio content not featured on the podcast. If you're not already a subscriber, we encourage you to become one. For more information, please visit the link in the show notes.  Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum: Lifelong Learning in Neurology. Today I'm interviewing Dr Lisa Silbert, who recently served as Continuum's co-guest editor for our latest issue on dementia alongside Dr Lianna Apostolova. Dr Silbert is a professor in the Department of Neurology at Oregon Health and Science University of the School of Medicine in Portland, Oregon, where she's also the director of the Neuroimaging Core and now the co-director of the Alzheimer's Disease Research Center. She also serves as director of the dementia clinic at the VA Portland Healthcare System. Which, Dr Silbert, sounds like a lot of work? Anyway, welcome. I really appreciate you taking the time to join us today and co-guest editing this issue. Why don't you introduce yourself a little bit to our listeners?  Dr Silbert: Well, thank you so much for interviewing with me today and for inviting me to be the guest, co-guest editor of this issue. It's a really exciting time for dementia care and dementia research. As you already said, my name is Lisa Silbert. I'm in Oregon Health and Science University in Portland, Oregon. I've been involved in caring for dementia patients and their families for over twenty years now and been involved in a lot of really exciting research during that time. But I would say now is probably the most dynamic time in dementia research and care that I've seen. So, it's really, really exciting to be here.   Dr Jones: It really is an interesting time. So, I look back  in our last issue of Continuum focusing on dementia came out in 2022, which doesn't sound like that long ago, but a lot has changed, right? With the anti-amyloid monoclonals for Alzheimer's disease, new biomarkers and so on. And as the guest editor, you have this unique view, Dr Silbert, of the issue and the whole topic of dementia. As you were reading these really outstanding articles, what was the biggest “aha” moment for you or the biggest change in practice that you saw that's come up over the last couple of years?     Dr Silbert: I think, you know, in reading through the different manuscripts or chapters in this issue, it really struck home the advances that have been made throughout all the different areas of dementia. Not just- so, we hear a lot about Alzheimer's biomarkers and Alzheimer's treatments on the horizon, which is really exciting, but this is happening across other dementias as well. There's biomarkers on the horizon for a Lewy body disease and potentially for some of the frontaotemporal dementias. And so that to me really struck home as this is really, across the board, a change in the entire field that we're looking at.  Dr Jones: That is exciting. And I'd like to come back to some of those biomarker developments because I think that's an area where we've really been lacking in neurology as a specific way to diagnose those disorders. I think a topic which you just alluded to that a lot of our listeners and readers are thinking about are those antiamyloid monoclonal therapies for Alzheimer's disease. So, addicanumab, lecanumab and most recently the approval of donanemab. For these drugs specifically, how are you using them in your practice and how should our listeners be thinking about these drugs?  Dr Silbert: These are, you know, relatively new, really exciting new and emerging therapies for Alzheimer's disease. They are shown to remove amyloid from the brain. Patients who have clinical manifestations of Alzheimer's disease, and that is those in the stages of mild cognitive impairment or mild dementia. We are using lecanemab at Oregon Health and Science University through our therapeutics and clinical units. It's a really exciting time and it's a time where we have to be, also, cautious about who undergoes these therapies. So being really informed about the use, who's appropriate to undergo these therapies, what kind of safety tests need to be undergone, how do you assess risk in individual patients so that you can counsel them.  So, all of these factors need to be weighed in when you're making a decision about whether or not to treat a patient with a monoclonal antibody therapy. And specifically, we do neuroimaging to assess whether there are already the presence of microhemorrhages in the brain. We do genetic testing to look for APOE 4 genotypes that can increase the risk of Aria, which is amyloid-related imaging abnormalities. And all of these factors go into how we counsel patients and discuss whether or not to pursue treatment with monoclonal antibodies.    Dr Jones: So certainly a complex patient selection process and drug administration and monitoring of therapy for those patients.  And that- it brings to mind for me how we already have too few neurologists in the US. And now for a really prevalent disorder, Alzheimer's disease, we're making it a lot more complicated to deliver these new disease-modifying therapies. What do you think or what do you see as the role of the neurologists in caring for patients with dementia? And do these developments change that role?  Dr Silbert: For now, I think these developments make it even more important in a way that neurologists are involved in making a very specific clinical diagnosis of which dementia is playing a factor in the patient 's clinical presentation. I think one thing to note is with these emerging biomarkers, a lot of them can be positive before there are clinical symptoms and multiple etiologies are also very prevalent. And so just having one positive biomarker, it doesn't necessarily tell you what's going on with an individual patient. You need to take the whole picture into consideration. So, I think a really detailed evaluation by the neurologist, especially with these emerging therapies that have potential risks, is extremely important right now. Just getting a test is really not sufficient. You really have to take the entire clinical picture into account and know the ins and outs of the risks involved in these disease-modifying therapies.  Dr Jones: Which brings us back to something you mentioned earlier, right? Which is good news. We have on the horizon new potential biomarkers for other neurodegenerative causes of dementia. I can foresee and maybe I'm, you know, being an alarmist here, Dr Silbert, but if we have sensitive biomarkers for other neurodegenerative conditions, we know patients often have copathologies. Is that going to help clarify things? Is it going to confuse us? How is that going to work?  Dr Silbert: Well, I think ultimately, it's going to help clarify things. Because there are multiple pathologies that are common in age related cognitive impairment, any kind of additional specific input that we can get with different biomarkers is going to be helpful in putting the pieces together to come up with what's happening clinically with each individual patient. Ultimately, I think these biomarkers, they're not- any one biomarker isn't going to be a solution to diagnosis, but putting them together to help improve early and accurate diagnosis is really the goal here. Having a very early diagnosis, having a very accurate diagnosis will improve our ability to give prognosis and also improve effective treatment strategies moving forward. I think that these biomarkers have the promise in facilitating that for us.  Dr Jones: And progress is always a good thing. We just have to learn how to adapt and use the evidence appropriately. There have been and I think most of our listeners will be familiar with some of the controversies related to these, these new disease-modifying drugs for Alzheimer's disease. Do you want to walk us through a couple of those, and what are your thoughts about those controversies?  Dr Silbert: Yeah, these new therapies, they're very exciting for everyone in the field, but they, like you mentioned, they're not without their controversies. I think one controversy or one potential downside to these therapies is access to them. Like you already mentioned there, there's really not enough neurologists out there. There's not enough behavioral neurologists out there. There's limitations to infusion centers, sites and prescribers. Access to these therapies is is significantly limited. They are requiring infusions quite frequently. So, if you're not living near specialty care, you're not really able to feasibly undergo these kinds of treatments. Another controversy is the fact that the treatment effects are considered by some to be fairly modest when looking at the clinical data and in association with that, there are risks involved. Like I already mentioned, there's the amyloid-related imaging abnormalities, which sounds kind of like a benign thing, but they really consist of microhemorrhages that can lead to bigger hemorrhages and edema in the brain. These risks are relatively small - they are seeing more commonly in those who have a specific genotype, an APOE E 4 genotype - but they're risks nonetheless.  And so, there's controversy about the risk-benefit ratio and access to care with these new therapies.  Dr Jones: It's very exciting, but we should be cautious, right? I recall a few years ago as a program director, a neurology residency program director, interest in different areas of neurology would often follow developments in those areas, right? Lots of interest in autoimmune neurology when those developments would proceed in neuro oncology, etc. And I wonder if the therapeutic advances in in behavioral neurology and neurodegenerative cognitive disorders, I wonder if that's going to stimulate interest among our trainees to pursue behavioral neurology? Do you have a view on that or have you seen much change in interest in in this field?  Dr Silbert: You know, we are seeing a lot more interest in our trainees. The residents are very interested in these new therapies and how to apply them. And I'm really excited about that.  I'm hopeful that this will stimulate interest in the field. And we need those specialists, we need those sub specialists to undergo fellowship training in behavioral neurology and geriatric neurology so that we have more access to the subspecialty care and delivering these new therapies. So, I agree with you, I'm hopeful about it and I am seeing new interest in our trainees about these new therapies.  Dr Jones: We can hope so. And all the other fellowship directors will be anxious if neurology residents start leaving to go into behavioral neurology. But there's certainly demand. And I know that under the best of circumstances, dementia is so common. It's something that we have to care for in partnership with primary care and community resources. And these disease-modifying therapies capture a lot of attention, but it's really a small part of the continuum of care of these patients. And Dr Silbert as an expert, you know, if we put that disease-modifying therapy to the side for a second and just said, well, what are the biggest gaps in the care for patients with dementia? What do you see as those biggest gaps and, and what can we do to fix them at not just a neurology level, but at a societal level?  Dr Silbert: That's a big question. And you know, what I see almost every day are gaps in the support mechanisms for families who are caring for patients with dementia. These caregivers are under a lot of stress and oftentimes they just don't have the resources to take care of somebody who at some point will often need twenty-four hour care and supervision. Caregivers are older, usually of older age themselves and have their medical issues as well. And then we're just not doing a good job as a nation in in supporting patients and their families with like supportive care and respite care that's really needed. So, you know, I'm not just seeing and treating patients with dementia, but I'm seeing and I'm really trying to support and care for those who are taking care of patients with dementia. To me, that's the biggest gap in our system. Dr Jones: Yeah. And as I look through this issue of Continuum, we touched on not only the conventional topics in dementia and behavioral neurology. I'm really happy in hindsight that we have invited some discussion of the psychiatric symptoms in dementia, which I think are really important and often underrecognized and maybe undermanaged or mismanaged, and really also focusing on the caregiver burden and support services. We do have an article dedicated to that as well, and I think that'll be useful to our readers and listeners when we when we publish those podcasts. We we've heard this year especially a lot of public conversation about cognitive impairment and dementia. I sometimes wonder if that public attention is helpful and constructive for the population of patients with dementia. Sometimes I wonder if that conversation is counterproductive. What's your take on that?  Dr Silbert: You know, I think it's- it can be a mixed bag, but ultimately, it's in the conversation. We're talking about it. And I think that's only a good thing. There's more public awareness of it.  There is more interest in therapies. So, I think at the end of the day, talking about it, making it more prevalent in the ether, it stimulates the conversation and discussion. And even if there's controversies about it, we're talking about it. And I think that's kind of the first step in acknowledging that we need more support, we need more therapies.  Dr Jones: Yeah, I agree. And I think often patients with neurologic disorders and their caregivers and families often appreciate being seen.   Dr Silbert: Yeah, no, absolutely true. So, I'd say in regards to the monoclonal antibody treatments, you know, despite the controversies with these new treatments, I think there's a real promise and a real hope and a real excitement across a lot of behavioral neurologists, including myself, that this is just the beginning. That even if these first line, first generation therapies maybe have downsides, that there'll be second generation and third generation variations on these kinds of treatments that are going to be more accessible, have less side effects and hopefully be more clinically effective. And, and down the line, the other real hope for the field is that these maybe second generation therapies will actually delay the onset or prevent clinical manifestation of the disease. And that's the real goal here.  Dr Jones: And that's a great segue to the to the next thing I wanted to ask you about and you, you may have already answered the question. We talked about how we have and will have new biomarkers which will help us with diagnosis. We have hopefully the first phase in increasingly effective disease modifying therapies for Alzheimer, maybe prevent Alzheimer's disease. Wouldn't that be great? Are there any other things on the horizon that you see maybe for other neurodegenerative disorders from a therapeutic perspective? What do you, what do you think the next big thing will be in that area?  Dr Silbert: Well, that's a great question. I think, you know, there's a lot of exciting research in Lewy body dementia and targeting alpha synuclein pathologies. We really need biomarkers.  So, we're ways off from therapeutics, but I think there's a lot of exciting progress in that area.  Dr Jones: So, like many areas of neurology, there are rewarding and challenging aspects to the care of these patients. What  do you- what's the most rewarding aspect of your practice, Dr Silbert?   Dr Silbert: You know, a lot of… I hear from trainees over the years that, you know, they can't imagine or it's difficult for them to think about caring for patients who have a neurodegenerative disease that has no cure. But I feel like that's a lot of what neurologists do. We don't necessarily cure all diseases, but we treat the patient throughout their disease process. And to me that is extremely satisfying. You know, I enjoy listening to patients' stories and hearing about what they have been through over the years. And I really feel, like, appreciated for the care that I provide in giving not just an accurate diagnosis, which a lot of people come in lacking, but talking about future planning and, really, treatment throughout the course of the disease. And I was in clinic yesterday and talking to one of my patients' caregivers, and we were talking about a particularly difficult behavioral manifestation that her husband was going through. And we were talking through how to manage it. And she said to me, you know, Dr Silbert, I really feel like I have a partner in going through this disease. And you know, that's kind of what it's all about for me. So, to me, it's extremely rewarding field. It's also a very exciting field, especially right now with all these new biomarkers and treatments. So, I just think there isn't a better area of neurology to be involved in right now.   Dr Jones: What a great place to land and end the interview. And I hope our listeners and our readers really do enjoy this issue. It's really a fantastic, not just an update, but a survey of a very dynamic aspect of the field of neurology. And Dr Silbert, I want to thank you for joining us and thank you for such a thorough and fascinating discussion on caring for patients with dementia.    Dr Silbert: It was my pleasure. Thank you.    Dr Jones: Again, we've been speaking with Dr Lisa Silbert, co-guest editor, alongside Dr Leanna Apostolova for Continuum 's most recent issue on dementia. Please check it out, and thank you to our listeners for joining us today.  Dr Monteith: This is Dr Teshamae Monteith, associate editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. Thank you for listening to Continuum Audio. 

Adrenal Insufficiency for the Pediatric Anesthesiologist with Melinda Pierce, MD, MCR

「いつも眠い人は危険!?「日中の眠気」と「熱意の低下」は認知症の前段階である可能性」　日中に眠気があり、活動への熱意を奮い起こすことが困難な高齢者は、そうした症状のない高齢者に比べて、認知症の前段階の一形態である運動認知リスク症候群（motoric cognitive risk syndrome；MCR）になるリスクが3倍以上高いことが、新たな研究で明らかになった。MCRは主観的認知機能の低下と歩行速度の低下が併存した状態を指す。米アルバート・アインシュタイン医科大学のVictoire Leroy氏らによるこの研究の詳細は、「Neurology」に11月6日掲載された。

This week, the gang celebrate Dylan's third decade by checking out his picks for birthday albums this year: Fleetwood Mac's "Rumours", The Killers' "Hot Fuss", My Chemical Romance's "Danger Days: The True Lives of the Fabulous Killjoys" and Ghost's "Rite Here Rite Now." Will Steve like his second MCR album? Can BC get behind the synth and keyboard sound of the Killers? Tune in to find out! Hosted by Steve Wright, Brian "BC" Chapman and Ryan "BB" Bannon Produced by Dylan Wright Music by Mark Sutorka Spotify Playlist: https://open.spotify.com/playlist/02Yss8FgCDJ0XEoLUcGCIx?si=F7vXCGEPQmmiSDCyXV5CFQ Facebook: https://www.facebook.com/PTHpodcast 

Adrenal Insufficiency for the Pediatric Anesthesiologist with Melinda Pierce, MD, MCR

Drew DePriest, MCR.w, WELL AP is Director of Real Estate Operations Technology at McKesson where he is passionate about innovating in the built environment using the latest CRE, facility management, and autonomous building strategies. Mike Petrusky asks Drew about the rapid pace of change in technology and the workplace and how he keeps up by engaging with industry connections while constantly being “a curious nerd”. Drew believes that data governance has become our paramount concern, so he leads his teams with a focus on ensuring data quality and accuracy. When considering new technologies, Drew shares his philosophy of identifying business outcomes rather than just jumping on the latest trends. Artificial intelligence has great potential to impact the built environment, so it's important to ensure the underlying data it learns from is accurate and complete. Mike and Drew agree that we must lead using change management strategies that put humans first, acknowledge our struggles and failures, and encouraging continuous learning and improvement as we seek to be a workplace innovator in our organizations. Connect with Drew on LinkedIn: https://www.linkedin.com/in/drewdepriest/ Learn more about McKesson: https://www.mckesson.com/about-mckesson/ Check out the “On My Way To Work” video series: https://www.youtube.com/playlist?list=PLSkmmkVFvM4E39sM-pNaGhLoG0dkM947o Discover free resources and explore past interviews at: https://eptura.com/discover-more/podcasts/workplace-innovator/ Learn more about Eptura™: https://eptura.com/ Connect with Mike on LinkedIn: https://www.linkedin.com/in/mikepetrusky/  

Donald Trump ja est

We finally made it to Vegas for another year of When We Were Young Fest. And guess what? We talked to a BUNCH of your faves (and soon to be new ones). From Atreyu to Movements, Daisy Grenade to Jimmy Eat World and more, we got the low-down on these acts.Check out all the interviews in the episode! But if you want to hear a specific one (or two), check out the timestamps:Intro & Recap: 0:00-15:553OH!3: 15:56-25:02Atreyu: 25:03-35:24August Burns Red: 35:25-40:21State Champs: 40:22-45:30Daisy Grenade: 45:31-53:33Jimmy Eat World: 53:34-62:33Boys Like Girls: 62:34-75:38Movements: 75:39-85:51Millionaires: 85:52-97:26The Devil Wears Prada: 97:27-106:46 You can check out our other videos on our YouTube channel.______CHECK OUT THE ACTS:3OH!3 | Atreyu | August Burns Red | State Champs | Daisy Grenade | Jimmy Eat World | Boys Like Girls | Movements | Millionaires | The Devil Wears Prada______INTERVIEWS ALL IN ONE PLACEWe created a fresh Interview Only YouTube channel. Make sure to go and give that a follow so you don't miss any of our upcoming chats with your favorite acts~______Make Me A Fan Spotify PlaylistCheck out our Spotify playlist for all of our upcoming episodes, so you can see if you'll become a fan yourself (if you aren't already) of these artists we're going through.______EMO SOCIAL PATREONIf you're looking for more content from us, subscribe to our Patreon FOR FREE or, if you want a lil' more access, it's only $1/month as we restart it! This includes content left on the cutting room floor, full interviews and more.______AFFILIATE LINKSTubebuddy has helped us reach a larger audience, streamline our videos, and perfect the way we use the algorithm. Try Tubebuddy today and support our channel.----Like the music on the channel? Need copyright-free music for your streams and YouTube videos? Check out Epidemic Sound!Use our link for a free, one-month trial. ______Join the club!Twitch: https://emosocialclub.tvDiscord: https://emosocial.club/discordTikTok: https://www.tiktok.com/@xemosocialclubxTwitter: https://emosocial.club/twitterInstagram: https://emosocial.club/instagramYoutube: https://emosocial.club/youtubeFacebook: https://emosocial.club/facebook  Follow us!Brian: @spookypants1Lizzie: @bordenbathory

Gun Talk Hunt's Kevin “KJ” Jarnagin is joined by Willie Vernon of Christensen Arms. In this wide-ranging - sometimes off-the-rails - discussion, KJ and Willie cover how to correctly pronounce “Christensen”, their phenomenal MCR rifle, how to choose the right long gun for your hunt, the best way to prepare bacon, and much more.Learn more about Christensen Arms here: https://christensenarms.com/Learn more about the MCR here:https://christensenarms.com/modern-carbon-rifle/Shop Christensen Arms rifles here: https://snp.link/174ec6c3This Gun Talk Hunt is brought to you by: EOTECH, Rossi USA, Timney Triggers, Range Ready Studios, Silencer Central and Vortex Optics.For more content, subscribe to Gun Talk at guntalktv.com, on Gun Talk's Roku, Apple TV, iOS app, Android app, or find Gun Talk on YouTube, Facebook, Instagram, X and guntalk.com. Listen to all Gun Talk Podcasts with Spreaker, iHeart, Apple Podcasts, Spotify or wherever you find podcasts.Copyright ©2024 Freefire Media, LLCGun Talk Hunt 09.13.24

Lena Thompson, IFMA Fellow, FMP, SFP serves on the IFMA Global Board of Directors, Kay Sargent, FASID, FIIDA, CID, LEED® AP, MCR/w, WELL AP is Senior Principal & Director of Thought Leadership, Interiors at HOK, Mayra Portalatin, SFP, LEED AP is Vice President of Facilities Services at NVE, Inc., and Geoff Snavely, LEED AP is Vice President & General Manager at milliCare by EBC Carpet Services. Mike Petrusky hosts a roundtable discussion with these industry-leaders as they prepare to present a session called “Radical Change in FM: Lean In or Be Left Behind” at IFMA's World Workplace 2024 in San Antonio, TX on October 11 at 10:30am CDT. Change has always been the one constant, but now we're in a period of radical change for FM, real estate, and the workplace. This panel will look at the new frontier of the built environment from many perspectives – FM practitioners, workplace consultants, and industry partners — and why we must all be leaders who are not afraid to upskill, leverage tech, and “be comfortable being uncomfortable”. As we navigate through an uncertain future, remember to enjoy the ride and be a Workplace Innovator! Connect with Lena Thompson, FMP, SFP on LinkedIn: https://www.linkedin.com/in/lena-thompson-5b05a86/ Connect with Kay on LinkedIn: https://www.linkedin.com/in/kay-sargent-53b2431/ Connect with Mayra on LinkedIn: https://www.linkedin.com/in/mayraportalatin/ Connect with Geoff on LinkedIn: https://www.linkedin.com/in/geoffsnavelymillicare/ Register for IFMA's World Workplace: https://i.snoball.it/p/jeVL/l/3 Discover free resources and explore past interviews at: https://eptura.com/discover-more/podcasts/workplace-innovator/ Learn more about Eptura™: https://eptura.com/ Connect with Mike on LinkedIn: https://www.linkedin.com/in/mikepetrusky/  

To celebrate 20 years since My Chemical Romance hit the mainstream with their masterpiece album, Three Cheers For Sweet Revenge, Adam and Mike listen to the album in full and talk about this album's impact on their lives and on their music tastes. As we await whatever comes next from this band going into the future, we reflect on their place in the rising boom on the emo scene back in the 00s and we even ponder if there'll be similar genre explosion with a band or an artist leading the way just like MCR did way back when.  We hope you enjoy our track-by-track review/celebration of one of our all-time favorite albums ‘Three Cheers For Sweet Revenge' by My Chemical Romance Also on the episode, we share our thoughts on albums from artists like Stand Atlantic, Mothica, Palaye Royale, Yours Truly, and That Woman. #MyChemicalRomance #ThreeCheersForSweetRevenge _______________________________________ Find us on social media: ⁠⁠⁠https://discord.gg/2jv87Wypvw⁠⁠⁠ ⁠⁠⁠https://www.twitter.com/TheSkinnyPod⁠⁠⁠ ⁠⁠⁠mail to:theskinnywithmikeandadam@gmail.com⁠⁠ --- Support this podcast: https://podcasters.spotify.com/pod/show/theskinnywithmikeandadam/support

This week we bring you our audio version of our reaction to Thursday's Full Collapse. This is a part of our When We Were Young Album Review series - you can check out this + our other videos over on our YouTube channel.______INTERVIEWS ALL IN ONE PLACEWe created a fresh Interview Only YouTube channel. Make sure to go and give that a follow so you don't miss any of our upcoming interview videos!______Make Me A Fan Spotify PlaylistCheck out our Spotify playlist for all of our upcoming episodes, so you can see if you'll become a fan yourself (if you aren't already) of these artists we're going through.EMO SOCIAL PATREONIf you're looking for more content from us, subscribe to our Patreon FOR FREE or, if you want a lil' more access, it's only $1/month as we restart it! This includes content left on the cutting room floor, full interviews and more.______AFFILIATE LINKSTubebuddy has helped us reach a larger audience, streamline our videos, and perfect the way we use the algorithm. Try Tubebuddy today and support our channel.----Like the music on the channel? Need copyright-free music for your streams and YouTube videos? Check out Epidemic Sound!Use our link for a free, one-month trial. ______Join the club!Twitch: https://emosocialclub.tvDiscord: https://emosocial.club/discordTikTok: https://www.tiktok.com/@xemosocialclubxTwitter: https://emosocial.club/twitterInstagram: https://emosocial.club/instagramYoutube: https://emosocial.club/youtubeFacebook: https://emosocial.club/facebook  Follow us!Brian: @spookypants1Lizzie: @bordenbathory

Interview with Kelly C. Young-Wolff, PhD, MPH, author of Prenatal Cannabis Use and Maternal Pregnancy Outcomes, and Jamie O. Lo, MD, MCR, author of Associations Between Prenatal Cannabis Use and Maternal Health Outcomes. Hosted by Eve Rittenberg, MD. Related Content: Prenatal Cannabis Use and Maternal Pregnancy Outcomes Associations Between Prenatal Cannabis Use and Maternal Health Outcomes

Interview with Kelly C. Young-Wolff, PhD, MPH, author of Prenatal Cannabis Use and Maternal Pregnancy Outcomes, and Jamie O. Lo, MD, MCR, author of Associations Between Prenatal Cannabis Use and Maternal Health Outcomes. Hosted by Eve Rittenberg, MD. Related Content: Prenatal Cannabis Use and Maternal Pregnancy Outcomes Associations Between Prenatal Cannabis Use and Maternal Health Outcomes

On this episode of the Massimo Show Rod sits down with Ken Ashley, CCIM, MCR, SIOR, Executive Director of Cushman & Wakefield and Founder of CREI, Commercial Real Estate Influencer. Ken is a successful Atlanta broker with nearly 30 years experience with tenant representation and sales in the commercial real estate industry.  They discuss the importance of building a personal brand and using social media effectively in the commercial real estate industry. Ken shares his strategies for engaging with prospects, valuing your time, and creating a strong online presence. He emphasizes the need to focus on the other person and provide value in order to build trust and influence. Ken also announces the upcoming CREI Summit, a conference dedicated to helping commercial real estate professionals build their brands and increase their influence. Note: These highlights are designed to provide an overview of this episode's content. Listeners are encouraged to tune in to the full episode for a comprehensive understanding of the topics covered. At the Massimo Group we have 15 years of experience helping the most dedicated brokers, like you, build the CRE business and life they have always desired. If you'd like to learn more visit https://massimo-group.com/

This journal club episode comes to you from the 2024 Tri-State Dairy Nutrition Conference. The paper is “Practical Aspects of Reducing Carbon Footprint by Dairy Farms Through Feeding” from the conference proceedings.In the U.S., livestock competes with oil and gas for the top source of methane emissions. While “carbon-neutral” agriculture may be easy for modelers to show, Dr. Hristov feels this is misleading and probably impossible in practical dairy farming. However, mitigation can be addressed in several directions, and nutrition can have perhaps the largest impact. Management practices, genetic selection, and manure management can be added to achieve large reductions in total methane from an intensive dairy production system. (2:43)As forage digestibility increases, methane yield and intensity will decrease. A forage with higher digestibility may gain a 10-15% improvement in methane intensity compared to a lower digestible forage. In addition, starch makes less methane than NDF does. Feedlot cattle produce half the methane of a normal dairy cow due to the increased starch in the feedlot diet. We know fats and lipids can decrease methane, but anything higher than 5-6% in the diet will disturb rumen function and lead to poorer performance. Comparing different forages, corn silage produces the least methane, with alfalfa in second place. (6:41)Feed additives have the potential to deliver compounds for methane mitigation. One of these is 3-nitrooxypropanol (3-NOP), the commercial version of which was developed in Europe. It is approved in Europe and Latin American countries. Australia and New Zealand are also working through the approval process. This compound inhibits the MCR enzyme (methyl coenzyme M reductase) which catalyzes the last step in methanogenesis. Dr. Hristov's lab has consistently shown a 30% reduction in methane yield when diets containing 3-NOP are fed, with no impact on milk production and a slight increase in milk fat. 3-NOP is quickly metabolized, so it is most useful in a confinement system where it can continuously enter the rumen. The compound is stable in a TMR for up to 24 hours, and the optimum inclusion rate is 60-80 milligrams per kilogram of diet (60-80 ppm). (14:41)Regarding regulatory approval in the U.S., the FDA has indicated that 3-NOP must be approved as a drug, not as a feed additive. Dr. Hristov has concerns about an adaptation of the cows to the compound. One study in Holland fed 3-NOP for a year, and there was a definite decrease in efficacy over time. Furthermore, efficacy may depend on diet, as 3-NOP is less effective with high NDF diets. It's unclear if the decrease in efficacy over time is because the microbes break down 3-NOP before it affects methane synthesis or if the microbes shift to a different pathway of methane synthesis. (22:04)Bromoform, a compound found in red seaweeds, is also a powerful methane mitigator. Dr. Hristov's lab has observed 60-65% decreases in methane production early in the feeding period, dropping to 20-25% after 200 days. Other issues include the practicality of growing and transporting seaweed, the instability of bromoform, and the fact that bromoform is an ozone-depleting compound and a carcinogen. Seaweed extracts tend to decrease dry matter intake, and thus milk production and milk iodine increase dramatically. (25:54)In the U.S. dairy system, where manure is usually handled as a liquid, methane emissions from manure and from the cow are equal. Methane digesters and flaring of methane are common mitigation methods. Acidification is another method whereby decreasing pH can decrease methane emissions and ammonia and nitrous oxide losses. Dr. Hristov predicts a lot of additives to decrease methane emissions from manure will eventually be available on the market. (31:16)3-NOP has little effect on rumen dynamics but may increase butyrate. Dr. Weiss asks if different feed additives have synergistic effects, and Dr. Hristov thinks much more work is needed in this arena. (33:19)While methane mitigation probably has no silver bullet, many little interventions can add up to a big impact. Looking forward, so many people are working in this area; we will have solutions for methane mitigation. (43:56)Please subscribe and share with your industry friends to invite more people to join us at the Real Science Exchange virtual pub table.  If you want one of our Real Science Exchange t-shirts, screenshot your rating, review, or subscription, and email a picture to anh.marketing@balchem.com. Include your size and mailing address, and we'll mail you a shirt.

This week we bring you some reactception! We watch Hivemind's reaction to what the Top 10 emo bands are (of all time, apparently!) You can listen AND watch the video reaction too over on our YouTube channel.______INTERVIEWS ALL IN ONE PLACEWe created a fresh Interview Only YouTube channel. Make sure to go and give that a follow so you don't miss any of our upcoming interview videos!______Make Me A Fan Spotify PlaylistCheck out our Spotify playlist for all of our upcoming episodes, so you can see if you'll become a fan yourself (if you aren't already) of these artists we're going through.EMO SOCIAL PATREONIf you're looking for more content from us, subscribe to our Patreon FOR FREE or, if you want a lil' more access, it's only $1/month as we restart it! This includes content left on the cutting room floor, full interviews and more.______AFFILIATE LINKSTubebuddy has helped us reach a larger audience, streamline our videos, and perfect the way we use the algorithm. Try Tubebuddy today and support our channel.----Like the music on the channel? Need copyright-free music for your streams and YouTube videos? Check out Epidemic Sound!Use our link for a free, one-month trial. ______Join the club!Twitch: https://emosocialclub.tvDiscord: https://emosocial.club/discordTikTok: https://www.tiktok.com/@xemosocialclubxTwitter: https://emosocial.club/twitterInstagram: https://emosocial.club/instagramYoutube: https://emosocial.club/youtubeFacebook: https://emosocial.club/facebook  Follow us!Brian: @spookypants1Lizzie: @bordenbathory

In this episode, we're joined by Nathan and Genevieve from the band Soul Meets Body. We talk with Nathan about Neil Young's album "On The Beach", and end up shocking him with some true crime lore on a certain track. Then we dive into MCR's "Danger Days...." with Genevieve; we talk comic books, the genius of Gerard Way, and the lore behind MCR.

NAPTIME with Dr. Miyabe Shields. Thank you to MCR labs for sponsoring this episode and donating to NAP: https://mcrlabs.com/ Nothing in this podcast is ever medical advice, consult a medical professional for advice about your health needs. Sign up for the Effective Cannabis Newsletter: https://www.effectivenewsletter.com/ecn Take our survey: https://btstudi.es/q/napbaseline/ Learn more about NAP: https://appliedpharmacognosy.org/ Donate to NAP: https://givebutter.com/KEZGuw

Can you remember your first concert or the thrill of buying your first album? Our guest for this episode, the self-taught musician and radio personality, Ron Coolen, takes us down memory lane to his early experiences with music. He shares his affinity for heavy metal music, sparked off by his first album purchase, Boston's "Don't Look Back." A resident of Amsterdam, Ron is a family man who has chosen his passion for music over the city's famous nightlife.Our journey through the world of heavy metal doesn't end there. We reflect upon the bands that have shaped our musical tastes over the years, from ACDC and Van Halen to the more modern bands like Slipknot and Korn. We explore the impact of singers joining established bands and consider the change it brings in the group dynamics and sound. Touching upon concerts, we reminisce about the magic of floor standing and shoulder rides, a lost tradition in the modern gig scene.Ron continues to inspire us with his story of perseverance and passion. His journey from a dreamer to a successful musician is a testament to the power of following your dreams. We end our conversation with a sneak peek into Ron's upcoming album, symbolizing his commitment to continue creating music that people appreciate. Join us on this musical journey, it's filled with soulful stories and inspiration, all served with a heavy dose of rock'n'roll.Watch the full episode on YouTubeCheck out the Playlist on SpotifyFollow us EverywhereMake sure to HIT that LIKE BUTTON and SUBSCRIBE to our Channel to be notified of new episodes!Please share our page with your friends! A new episode is out every Monday at 12 pm Rock onSupport the show

ICYMI our react video to listening to every album that's being played at WWWYF 2024, don't worry, you can now listen to it in podcast form. It's also longer and (mildly) unedited, so you get 2x the bad takes as we review MCR's The Black Parade.______EMO SOCIAL PATREONIf you're looking for more content from us, subscribe to our Patreon FOR FREE or, if you want a lil' more access, it's only $1/month as we restart it! This includes content left on the cutting room floor, full interviews and more.______CHICAGO READER BEST OF 2023 VOTINGWe're nominated for Chicago Reader's "Best Of 2023" for "Best Music Podcast" in Chicago. Voting starts on Dec. 13 at 12pm CST and ends on Jan. 14 at midnight. To vote and to check out other nominees visit their site. Join the club!Twitch: https://emosocialclub.tvDiscord: https://emosocial.club/discordTikTok: https://www.tiktok.com/@xemosocialclubxTwitter: https://emosocial.club/twitterInstagram: https://emosocial.club/instagramYoutube: https://emosocial.club/youtubeFacebook: https://emosocial.club/facebook  Follow us!Brian: @spookypants1Lizzie: @bordenbathory

Vik Bangia, MCR is CEO of Verum Consulting where he is a Corporate Real Estate & Facilities Management Outsourcing Advisor and advocate for the employee-centric workplace. Mike Petrusky asks Vik how to create more employee-centric, role-specific hybrid models that replace unpopular one-size-fits-all return-to-office mandates. They explore a holistic view of work and the workplace and agree that work-life balance is not a seesaw but rather an integration of different aspects of one's life, including our work. Vik believes that the balance of power is shifting with employees now having a say in how much time they need to spend in the office to get their work done and he shares data showing that employee engagement increases when work policies are determined collaboratively, rather than being mandated. Mike and Vik offer practical advice to help you create a bespoke, customized experience for your employees as they seek to inspire you to be a Workplace Innovator in 2024! Connect with Vik on LinkedIn: https://www.linkedin.com/in/vik-bangia-mcr-0b54522/ Learn more about Verum Consulting: https://verumconsulting.com/ Watch the full hour-long video with Mike and Vik: https://lp.eptura.com/webinar-balancing-the-work-life-equation.html Explore the latest Eptura Workplace Index Report: https://lp.eptura.com/content-eptura-workplace-index-Q3.html Discover free resources and explore past interviews at: https://www.workplaceinnovator.com/ Learn more about Eptura™: https://eptura.com/ Connect with Mike on LinkedIn: https://www.linkedin.com/in/mikepetrusky/  

Interview with Myriam Loyo, MD, MCR, and Theda Kontis, MD, authors of Gender Equality in Facial Plastic Surgery—A Female President's Perspective. Hosted by Paul C. Bryson, MD, MBA. Related Content: Gender Equality in Facial Plastic Surgery—A Female President's Perspective

Prepare for a wild ride as we go backstage with Baranot Regrets and Sid Stratton to uncover the magic and mayhem of the music world. Our journey starts with a nostalgic trip down memory lane as Sid reveals his life-long love affair with music, triggered by the iconic Batman Forever soundtrack. Hear his fond recollections of partying with Jimmy Buffett, his parents' favorite musician, and how music can transport us back in time, igniting forgotten memories and emotions. We then step into the pulsating world of live music, where pyrotechnics and theatrics reign supreme. Sid grants us a backstage pass to his electrifying performances and the dynamic world of live shows, from the larger-than-life spectacles of bands like AC/DC and Motley Crue to the challenges and triumphs of the industry. We delve into the creative process behind album covers and the importance of trust in the high-stakes world of music production. Our conversation takes a spookier turn as we discuss horror movie nights and the iconic soundtracks that accompany them. From the unforgettable tunes of Batman Forever and Queen of the Damned to the timeless classics of Rocky Horror Picture Show, we explore the unique relationship between film and music. We also entertain the idea of sending our music to Quentin Tarantino, famed for his eclectic soundtracks. Join us for this compelling journey into the heart of the music industry, filled with priceless insights, laughter, and unforgettable tales.Check out Sid StrattonWatch the full episode on YouTubeCheck out the Playlist on SpotifyFollow us EverywhereMake sure to HIT that LIKE BUTTON and SUBSCRIBE to our Channel to be notified of new episodes!Please share our page with your friends! A new episode is out every Monday at 12 pm Rock onSupport the show

Pulpmx30 code to save at FXR Racing.com and Pulp20 code at Race Tech to save. We talk to the MCR rider on his great WSX ride in Aussie, the series in general, his 2024 SX plans, SMX, Friese, thoughts on the Lawrence brothers and more.

On this episode, Derek sits with Helané Wahbeh, ND, MCR.  Helané is the Director of Research for the IONS Institute.  She will be discussing her extensive research into channeling and intuition.  She will also be discussing her book, “The Science of Channeling: Why You Should Trust your Intuition and Embrace the Force That Connects Us All”. IONS: https://noetic.org/profile/helane-wahbeh/LinkedIn: https://www.linkedin.com/in/drwahbeh/Twitter/X: https://x.com/DrWahbeh?s=20Facebook: https://www.facebook.com/DrWahbeh/SPONSOR - Go to https://betterhelp.com/derekduvallshow for 10% off your first month of therapy with @betterhelp and get matched with a therapist who will listen and help #sponsored

Katy Redmond, MCR is Co-Lead for IPS Americas & Brokerage Tech Sector Lead at JLL where she is passionate about helping organizations with practical and innovative strategies for connecting "people, place and profit”. Mike Petrusky asks Katy for an update on her role at JLL and they explore how we can embrace technology and innovation to enhance the way real estate and facility management professionals work and improve their decision-making processes. They highlight the impact of A.I. and other related technologies in driving efficiencies, speed and ultimately your success in the industry. Katy shares the top five things that matter most to corporate occupiers today including return to the office strategies, sustainability, and talent retention. Mike and Katy agree that we should never stop learning and they share the value of IFMA and CoreNet for our personal and professional growth. Listen to get a better understanding about how FM tech tools and the power of data analytics can help you be a Workplace Innovator in your organization! Connect with Katy on LinkedIn: https://www.linkedin.com/in/katy-redmond-mcr-045a302/ Learn more about JLL: https://www.us.jll.com/ Explore the latest Eptura Workplace Index Report: https://lp.eptura.com/content-eptura-workplace-index-Q2.html Discover free resources and explore past interviews at: https://www.workplaceinnovator.com/ Learn more about Eptura™: https://eptura.com/ Connect with Mike on LinkedIn: https://www.linkedin.com/in/mikepetrusky/  

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: Abbott acquires Bigfoot, a new study looks at low-dose aspirin to prevent type 2, researchers look into whether the AI ChatGPT can answer FAQs about diabetes, Beyond Type Run is back for the NYC Marathon, and more! Our previous episode with Bigfoot Biomedical: https://diabetes-connections.com/?s=bigfoot Join us for Moms' Night Out! (use promo code School30 to save) Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza  Omnipod - Simplify Life Learn about Dexcom  Learn about Edgepark Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX Our top story this week – Abbott scoops up Bigfoot Biomedical. The deal is expected to close later this year – no financial terms yet disclosed. Abbott and Bigfoot have worked together since 2017 on a connected insulin pen system. Bigfoot Unity exclusively works with Abbott's FreeStyle Libre® Long time listeners will recall that Bigfoot was founded in 2015 around serving people with type 1 diabetes with a closed loop pump system that Byran Mazlish had developed for his wife and son. Mazlish was very secretive at first about the algorithm – this was before people were sure the FDA wouldn't crack down on them – so a journalist nicknamed him Bigfoot. Along the way, the company pivoted to CGM connected SmartPens. I believe Bigfoot was my third interview, back in 2015 – I'll ink up all of the interviews I've done with them in the show notes. https://diabetes-connections.com/?s=bigfoot https://www.prnewswire.com/news-releases/abbott-to-acquire-bigfoot-biomedical-furthering-efforts-to-develop-personalized-connected-solutions-for-people-with-diabetes-301918254.html XX Low-dose aspirin reduces the risk for type 2 diabetes among older adults and slows the increase in fasting glucose levels over time, new research finds. The data come from a secondary analysis of ASPREE, a double-blind, placebo-controlled trial of healthy adults aged 65 years or older, showing that 100 mg of aspirin taken daily for about 5 years did not provide a cardiovascular benefit but did significantly raise the risk for bleeding. It's a big study, more than 16-thousand people. This new analysis shows that individuals taking aspirin had a 15% lower risk for developing type 2 diabetes and that the medication slowed the rate of increase in fasting plasma glucose, compared with placebo, during follow-up. However, lead author Sophia Zoungas, MBBS, PhD, head of the School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia, says, "Major prescribing guidelines now recommend older adults take daily aspirin only when there is a medical reason to do so, such as after a heart attack… Although these new findings are of interest, they do not change the clinical advice about aspirin use in older people at this time." https://www.medscape.com/viewarticle/996058 XX A class-action lawsuit filed against Medtronic (NYSE: MDT)+ alleges that the company's insulin delivery devices shared patient data with third parties. The lawsuit — filed by the plaintiff “A.H.” in U.S. District Court in Central California — levels allegations against Medtronic and its MiniMed and InPen devices. It addresses MiniMed's transmission and disclosure of personally identifiable information and protected health information to Google and other third parties. Per the lawsuit, the data was transmitted via tracking and authentication technology, including Google Analytics, Crashlytics, Firebase Authentication and related tools. A.H. says these technologies, installed on the website and/or mobile applications, include the InPen iOS and Android applications. “Information about a person's health is among the most confidential and sensitive information in society, and its mishandling can have serious consequences, including embarrassment, discrimination, and denial of insurance coverage,” the lawsuit reads. A Medtronic spokesperson issued the following statement via email: We have strong processes, technologies, and people in place to safeguard and protect our information and systems, the information of our business partners, and most importantly, the privacy and safety of the patients and healthcare providers that use our products.” https://www.massdevice.com/lawsuit-patient-data-sharing-medtronic-diabetes/ XX Interesting new way to look at type 2 – not weight loss or medication, but about reducing how much blood glucose goes up and stays up after eating and drinking. University of Virginia Daniel Cox says this is called Glucose Everyday Matters, or GEM – aims to prevent blood sugar spikes via educated food and drink selection. This is coupled with physical activity to hasten recovery when blood-sugar spikes do occur. So someone might indulge in a piece of fruit or a small, sweet treat, knowing how it will affect them, and then go for an evening stroll to help even out their blood sugar. Sounds really simple, but in its first study, it helps almost 70-percent of people put their type 2 into remission without weight loss or medication. The National Institutes of Health has provided $3.5 million for a large-scale clinical trial Cox himself went from an A1C of 10.3 at the time of diagnoses to reading consistently under 6.0 for the past 13 years on no medication using his approach. https://newsroom.uvahealth.com/2023/08/31/radical-new-approach-to-managing-type-2-diabetes-receives-3-5-million/ XX Final preparations are in place to initiate the first clinical site for DIAGNODE-3 in the United States, and additional sites are expected to be initiated over the coming months. Approximately 10-12 clinical sites across the US are planned to be initiated, expanding the DIAGNODE-3 trial in the US and eight European countries to approximately 60 clincal sites in total. DIAGNODE-3 is designed to confirm the efficacy and safety of the antigen-specific immunotherapy Diamyd® in patients aged 12 to 29 years recently diagnosed with type 1 diabetes and carrying the genetic HLA DR3-DQ2 marker. Approximately 40% of all screened patients carry the genetic HLA DR3-DQ2 haplotype. This proportion aligns well with expectations based on previous Diamyd® clinical trials and published epidemiological research. Supported by published retrospective analyses and prospective clinical trials, the presence of the genetic HLA DR3-DQ2 haplotype determines the likelihood of responding to Diamyd® therapy, and serves as one of the main inclusion criteria in the DIAGNODE-3 trial. "Patient recruitment is a complex and central element in any trial and it is encouraging to see a significant and continuous uptick in the screening rate and that the observed frequency of the genetically defined responder group enrolled into DIAGNODE-3 confirms our previous observations", says Ulf Hannelius, President & CEO of Diamyd Medical. "This shows the operational and clinical feasibility of our precision medicine approach to Type 1 Diabetes and we look forward to expanding the trial to the United States". https://finance.yahoo.com/news/registrational-phase-iii-trial-type-142600082.html XX A low-carbohydrate diet during pregnancy may have some benefits in gestational diabetes, but overall, low-carbohydrate diets are not associated with any significant differences in outcomes. That was the conclusion of a presentation at the ADA Scientific Sessions. That was back in June but I just learned about it, so I'm passing along to you in case you missed it as well. During a debate at the American Diabetes Association Scientific Sessions, Amy M. Valent, DO, MCR, associate professor in the division of maternal-fetal medicine in the department of obstetrics and gynecology at Oregon Health & Science University, said identifying Teri L. Hernandez, PhD, RN, associate dean of research and scholarship in the College of Nursing and professor in the department of medicine and the division of endocrinology, metabolism and diabetes at the University of Colorado Anschutz Medical Campus, agreed that the first line of therapy with gestational diabetes is nutrition. However, Hernandez said, low-carbohydrate diets are not the only approach in gestational diabetes treatment with nutrition. Currently, dietary advice for treating gestational diabetes is inconsistent, and current professional guidelines have limitations and biases, according to Valent. Different diet strategies include low-carbohydrate, low glycemic index and total energy restriction eating plans, according to Valent. Valent said ACOG guidelines recommended a low-carbohydrate diet for gestational diabetes until the most recently revised edition in January. Valent reviewed several major landmark studies demonstrating that gestational diabetes treatment can decrease pregnancy complications such as preeclampsia and large for gestational age infants. “These studies were in the era where treatment of diabetes in pregnancy involved recommending a low-carbohydrate diet,” Valent said. “The concern with lowering carbohydrates is the risk of consuming lower nutrient-dense foods and resulting in the body to produce ketones, which may be associated with negative effects on the developing baby.” “Pregnancy is dynamic. Nobody's the same today as they were yesterday. They're going to be different 1, 2 or 3 weeks from now, and the nutritional demands and the fetal growth and development stage are going to be different,” Valent said. “So, nutritional demands are going to vary.” Hernandez also added that women and girls tend to be priced out of good nutritional patterns, which is an issue not only in the pregnancy field, but also in the global community. According to Hernandez, it is important to create ways moving forward to identify what nutritional patterns are best that are also affordable for families, especially in lower-income settings. https://www.healio.com/news/womens-health-ob-gyn/20230905/experts-debate-benefits-of-lowcarb-diets-for-gestational-diabetes XX XX Commercial – Edgepark XX Can ChatGPT help answer questions about diabetes? In a recent study published in the journal PLoS ONE, researchers tested chatGPT, a language model geared for discussion, to investigate whether it could answer frequently asked diabetes questions. In the present study, researchers evaluated ChatGPT's expertise in diabetes, especially the capacity to answer commonly requested questions related to diabetes in a similar manner as humans. The 'Frequently Asked Questions' section of the Diabetes Association of Denmark's website, viewed on 10 January 2023, included eight questions. The researchers designed the remaining questions to correlate to particular lines on the 'Knowledge Center for Diabetes website and a report on physical activity and diabetes mellitus type 1. Across the 10 questions, the proportion of correct responses ranged from 38% to 74%. Participants correctly identified ChatGPT-generated replies 60% of the time, which was over the non-inferiority threshold. Males and females had 64% and 58% chances of accurately recognizing the artificial intelligence-generated response, respectively. Individuals who had past contact with diabetes patients had a 61% chance of precisely answering the questions, compared to 57% for those who had no prior contact with diabetes patients. In contrast to the initial premise, participants could discern between ChatGPT-generated and human-written replies better than tossing a fair coin. While ChatGPT demonstrated some potential for accurately answering frequently asked questions, issues around misinformation and the lack of nuanced, personalized advice were evident. As large language models increasingly intersect with healthcare, rigorous studies are essential to evaluate their safety, efficacy, and ethical considerations in patient care, emphasizing the need for robust regulatory frameworks and continuous oversight. https://www.news-medical.net/news/20230905/Can-ChatGPT-be-a-diabetes-consultant-Study-probes-the-potential-and-pitfalls.aspx XX SAN MATEO, Calif., Aug. 24, 2023 /PRNewswire/ -- On November 5, diabetes nonprofit Beyond Type 1 will join more than 550 official charity partners and philanthropists raising awareness and funds while participating in the world's largest marathon, the TCS New York City Marathon. This year, the organization is expanding its 50-person team, Beyond Type Run, to include people living with type 1 or type 2 diabetes, as well as caregivers to those living with diabetes. "Since 2017, we've featured more than 200 runners on our teams who've exemplified what it means to survive and thrive with diabetes," said Beyond Type 1 CEO Deborah Dugan. Beyond Type 1 announces the 2023 NYC Marathon team to raise awareness and funds for people living with diabetes As a part of the Beyond Type Run team, runners will be advocating to raise awareness and funds for Beyond Type 1's portfolio of educational resources, awareness campaigns and peer-to-peer support programs for people impacted by diabetes. This advocacy is elevated through the NYRR Official Charity Partner Program, which offers opportunities for nonprofit organizations to raise funds to support their missions and services. Dexcom and Tandem Diabetes Care are presenting sponsors of Beyond Type Run for a fourth consecutive year. The TCS New York City Marathon Official Charity Partner Program has raised more than $440 million for more than 1,000 nonprofit organizations since its establishment in 2006. https://www.prnewswire.com/news-releases/team-of-50-individuals-impacted-by-diabetes-prepare-for-the-2023-tcs-new-york-city-marathon-301909163.html XX MNO update On the podcast next week.. tandem diabetes celebrity panel from friends for life – Hollywood, the NFL and NASCAR. Last week's episode was Benny off to college That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon. ----  

Taylor Swift's Eras tour is predicted to make a record $1 billion - but how? As countries around the world grapple with high inflation, how has Taylor Swift been able to persuade fans to spend money? Olivia Wilson speaks to Brittany Hodak, author of Creating Superfans, to understand the role Swiftomania has played in her commercial and financial success. Tyler Morse is the CEO of MCR, the third largest hotel owner-operator in the United States. He explains how Taylor Swift's concerts have had a significant impact on the local economies of the cities she has toured in – including some of his hotels in Phoenix, Arizona. Presented and produced by Olivia Wilson. (Image: Taylor Swift performing in Seattle. Credit: Getty Images)

Liz Anderson is back to talk about My Chemical Romance's 2006 album The Black Parade. Will she turn us into MCR heads? (is that what MCR fans call themselves?) You can follow Liz on TwitterWant to support the show and get bonus eps in our off-week? Pay what you can at our PatreonWant to reach out? Follow us on Twitter and Instagram  or email us at billbudspod@gmail.comLike the show? Leave us a review on iTunes!Theme by Arne Parrott! Go follow him on Soundcloud and Twitter

We are far too classy for a “Rocky Mountain High” joke. Live from SGIM 2023 in Aurora, Colorado!  We talk to a panel of Addiction Medicine specialists who recap their outstanding talk on all of the exciting developments in treating addiction.  We review major policy changes, trends in drug overdose, outpatient screening for alcohol use, and all of the ways we might be using psychedelics to treat addiction.  We are joined by Stefan Kertesz, MD @StefanKertesz (University of Alabama at Birmingham), Ximena Levander, MD, MCR, FACP @XimenaLevander (OHSU), Kenneth L. Morford MD, FASAM (Yale), and Katherine Mullins, MD, AAHIV @_kmullins_ (NYU Langone). Claim free CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Credits Producer: Carolyn Chan, MD and Paul Williams, MD, FACP Writer: Carolyn Chan, MD and Paul Williams, MD, FACP Show Notes, Infographic, and Cover Art: Paul Williams, MD, FACP Hosts: Carolyn Chan, MD; Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Leah Witt, MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guests: Stefan Kertesz, MD, MSc; Ximena A. Levander, MD, MCR, FACP; Kenneth L. Morford, MD, FASAM; Katherine Mullins, MD, AAHIV